8-K: Relmada Advances NDV-01 to Phase 3, Expands Pipeline

Relmada Therapeutics provides a mid-year update, highlighting strong Phase 2 NDV-01 data and plans for Phase 3, alongside progress for Sepranolone in Prader-Willi Syndrome.

Summary

• A comprehensive strategic review was completed, leading to portfolio expansion with two differentiated Phase 2 product candidates.
• NDV-01, a sustained-release formulation for non-muscle invasive bladder cancer (NMIBC), demonstrated impressive Phase 2 results with a 91% complete response (CR) rate at any time point.
• Preparations are underway to initiate a Phase 3 registrational trial for NDV-01 in the first half of 2026, including regulatory filings and manufacturing scale-up.
• The NDV-01 program was strengthened with the addition of Raj S. Pruthi, MD as Chief Medical Officer-Oncology, and Yair Lotan, MD as Chair of the Clinical Advisory Board.
• Sepranolone, being developed for compulsivity disorders such as Prader-Willi Syndrome (PWS), showed positive proof-of-concept data in Tourette's syndrome.
• A Phase 2 study for Sepranolone in PWS is planned for initiation in the first half of 2026, with regulatory engagement and manufacturing activities in progress.
• The company reported approximately $20.6 million in cash, cash equivalents, and short-term investments as of June 30, 2025, with no outstanding debt.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook with strong clinical data for NDV-01, strategic pipeline expansion, and clear plans for advancing both lead candidates. The financial position is stable with no debt, indicating good operational health for a clinical-stage company.

Positives

• NDV-01's Phase 2 study showed an impressive 91% complete response rate at any time point in non-muscle invasive bladder cancer (NMIBC), indicating strong efficacy.
• NDV-01 is positioned as a transformative, bladder-sparing therapy for NMIBC, a condition affecting approximately 600,000 patients in the U.S.
• The company is actively preparing to initiate a Phase 3 registrational trial for NDV-01 in the first half of 2026, signaling advancement towards commercialization.
• The NDV-01 program has been strengthened by the addition of two highly experienced bladder cancer experts, Raj S. Pruthi, MD, and Yair Lotan, MD.
• Sepranolone has shown positive proof-of-concept data in Tourette's syndrome, suggesting broad potential for compulsive disorders, including Prader-Willi Syndrome.
• The company maintains a healthy balance sheet with approximately $20.6 million in cash and no outstanding debt as of June 30, 2025.
• NDV-01's innovative sustained-release intravesical formulation provides prolonged tumor exposure to cytotoxic drugs (gemcitabine/docetaxel) while potentially reducing systemic toxicity.
• NDV-01 is designed for convenience, supplied as a pre-filled syringe ready for use and easily instilled via catheter in less than 5 minutes in a doctor's office.

Risks

• The potential for product candidates to progress as expected is not guaranteed.
• Phase 2 NDV-01 data may not continue to deliver positive results supporting further development.
• Clinical trials may fail to deliver statistically and/or clinically significant evidence of efficacy and/or safety.
• Top-line results may not accurately reflect the complete results of the trial.
• Planned or ongoing preclinical and clinical studies may fail to demonstrate expected results.
• Failure to secure FDA agreement on the regulatory path for NDV-01 and Sepranolone is a possibility.
• Future NDV-01 or Sepranolone clinical results may not be acceptable to the FDA.
• Failure to secure adequate NDV-01 or Sepranolone drug supply could impede development.

Future Outlook

Relmada Therapeutics is optimistic about its future, driven by the progress of NDV-01 and Sepranolone. The company plans to initiate a Phase 3 registrational trial for NDV-01 and a Phase 2 study for Sepranolone in Prader-Willi Syndrome in the first half of 2026, supported by ongoing regulatory engagement and manufacturing scale-up activities. The company aims for value creation through disciplined execution and capital-efficient development.

Management Comments

• "2025 has been a truly transformational year for Relmada Therapeutics."
• "We remain optimistic about Relmada's future. The progress of NDV-01 and sepranolone, combined with the expertise of our strengthened team, positions us well for value creation through disciplined execution and capital-efficient development."

Industry Context

The biotechnology industry continues to focus on developing innovative therapies for high-unmet-need areas like oncology and rare central nervous system disorders. Relmada's strategic expansion into non-muscle invasive bladder cancer (NMIBC) with NDV-01 addresses a condition with high recurrence rates and supply issues for existing treatments like BCG, positioning it as a potential bladder-sparing alternative. Its entry into Prader-Willi Syndrome with Sepranolone targets a rare genetic disorder with significant compulsive behaviors, leveraging proof-of-concept data from Tourette's syndrome, aligning with the industry's pursuit of novel mechanisms for neurological and rare diseases.

Comparison to Industry Standards

• NDV-01's 91% complete response rate at any time point in its Phase 2 NMIBC study compares favorably to existing treatments, especially given the high recurrence rates (50-80% over five years) and supply issues for the prior BCG standard.
• The Gem/Doce combination, which NDV-01 utilizes, is already embraced by the urologic oncology community, showing 2-year Relapse Free Survival (RFS) of ~50% as salvage therapy and 82% as first-line in high-risk BCG-naive patients, suggesting NDV-01's sustained-release formulation could enhance these outcomes.
• Competitors in NMIBC include UroGen (ZUSDURI Mitomycin C, low grade), Johnson & Johnson (TAR-200 Gemcitabine, high risk), and other emerging treatments like Nogapendekin alfa inbakicept (Anktiva) and Nadofaragene Firadenovec (Adstiladrin), which often have complex handling or device removal requirements, whereas NDV-01 is presented as a ready-for-use pre-filled syringe.
• Sepranolone's positive proof-of-concept data in Tourette's syndrome and its novel mechanism of normalizing GABA-A receptor activity without interfering with GABA signaling positions it uniquely for compulsive disorders like Prader-Willi Syndrome, an area with significant unmet needs and limited targeted therapies.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through successful clinical development and pipeline expansion. Positive clinical data and clear development path could attract new investors.
• Patients (NMIBC): NDV-01 offers a potential bladder-sparing, transformative therapy with high complete response rates, addressing a significant unmet medical need.
• Patients (PWS/Compulsivity Disorders): Sepranolone offers a novel therapeutic approach for a rare genetic disorder with significant compulsive behaviors, potentially improving quality of life.
• Employees: Strengthened team with new expert hires indicates growth and focus on key programs.

Next Steps

• NDV-01 Phase 2 nine-month results (Q4 2025).
• NDV-01 product supply scale-up (2H 2025).
• Sepranolone FDA engagement and manufacturing activities (2H 2025).
• NDV-01 Phase 2 twelve-month results (Q1 2026).
• U.S. IND clearance for NDV-01 (1H 2026).
• Initiation of Phase 3 registrational trial for NDV-01 (1H 2026).
• Initiation of Phase 2 PWS study for Sepranolone (1H 2026).

Key Dates

Recommendation

The filing highlights robust Phase 2 data for NDV-01, demonstrating a 91% complete response rate in NMIBC, and a clear path to a Phase 3 registrational trial in H1 2026. The strategic expansion into Prader-Willi Syndrome with Sepranolone, backed by positive proof-of-concept data, diversifies the pipeline with another high-potential asset. With a healthy cash balance of $20.6 million and no debt, the company is well-positioned to execute its development plans. These significant clinical and strategic advancements, coupled with a strengthened management team, suggest strong future value creation, making it an attractive investment for long-term growth.

Keywords

Biotechnology, Clinical-stage, Oncology, Central Nervous System, NDV-01, Sepranolone, Non-muscle invasive bladder cancer, NMIBC, Prader-Willi Syndrome, PWS, Drug development, Phase 2, Phase 3, Rare disease